84年鼠女哪年财运最旺,857comvvv色九欧美激情|85PO_87国产精品欲av国产av资源

[1]匡浩銘,楊張琪,彭志飛,等.六味地黃丸治療絕經(jīng)后骨質(zhì)疏松癥療效和安全性的Meta分析[J].中醫(yī)正骨,2022,34(08):31-35,58.
　KUANG Haoming,YANG Zhangqi,PENG Zhifei,et al.Clinical efficacy and safety of Liuwei Dihuang Wan(六味地黃丸)for treatment of postmenopausal osteoporosis:a meta-analysis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2022,34(08):31-35,58.
點(diǎn)擊復(fù)制

六味地黃丸治療絕經(jīng)后骨質(zhì)疏松癥療效和安全性的Meta分析()
分享到：

《中醫(yī)正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第34卷
期數(shù):
2022年08期
頁碼:
31-35,58
欄目:
文獻(xiàn)研究
出版日期:
2022-08-20

文章信息/Info

Title:
Clinical efficacy and safety of Liuwei Dihuang Wan(六味地黃丸)for treatment of postmenopausal osteoporosis:a meta-analysis
作者:
匡浩銘1; 楊張琪1; 彭志飛2; 戎寬2; 匡建軍2
(1.湖南中醫(yī)藥大學(xué),湖南 長沙 410208; 2.湖南省中醫(yī)藥研究院,湖南 長沙 410006)
Author(s):
KUANG Haoming1; YANG Zhangqi1; PENG Zhifei2; RONG Kuan2; KUANG Jianjun2
1.Hunan University of Chinese Medicine,Changsha 410208,Hunan,China 2.Hunan Academy of Chinese Medicine,Changsha 410006,Hunan,China
關(guān)鍵詞:
骨質(zhì)疏松; 絕經(jīng)后;  六味地黃丸;  專題Meta分析
Keywords:
osteoporosis; postmenopausal;  Liuwei Dihuang Wan;  meta-analysis as topic
摘要:
目的:系統(tǒng)評(píng)價(jià)六味地黃丸治療絕經(jīng)后骨質(zhì)疏松癥(postmenopausal osteoporosis,PMOP)的療效和安全性。方法:應(yīng)用計(jì)算機(jī)檢索中國知網(wǎng)、萬方數(shù)據(jù)庫、維普網(wǎng)、Cochrane Library、PubMed中有關(guān)六味地黃丸治療PMOP的隨機(jī)對(duì)照試驗(yàn)文獻(xiàn),檢索時(shí)限均為2012年5月31日至2022年2月31日。治療組干預(yù)措施為口服六味地黃丸(或以六味地黃丸為基礎(chǔ)適當(dāng)加減),對(duì)照組干預(yù)措施為口服西藥,2組均可聯(lián)合其他相同的治療措施。經(jīng)文獻(xiàn)檢索、文獻(xiàn)篩選、數(shù)據(jù)提取及偏倚風(fēng)險(xiǎn)評(píng)價(jià)后,采用RevMan5.3軟件對(duì)治療后疼痛視覺模擬量表(visual analogue scale,VAS)評(píng)分、治療后L2～L4骨密度、治療后血清堿性磷酸酶(alkaline phosphatase,ALP)含量及并發(fā)癥發(fā)生率進(jìn)行Meta分析,并采用漏斗圖進(jìn)行發(fā)表偏倚分析。結(jié)果:共納入10項(xiàng)隨機(jī)對(duì)照試驗(yàn),涉及1102例患者,治療組和對(duì)照組各551例。Meta分析結(jié)果顯示,治療組治療后疼痛VAS評(píng)分、血清ALP含量和并發(fā)癥發(fā)生率均低于對(duì)照組[MD=-1.03,95%CI(-1.29,-0.77),P=0.000; MD=-18.02,95%CI(-32.61,-3.43),P=0.020; OR=0.45,95%CI(0.23,0.90),P=0.020],治療后L2～L4骨密度高于對(duì)照組[MD=0.06,95%CI(0.02,0.09),P=0.003]。基于治療后L2～L4骨密度的發(fā)表偏倚分析結(jié)果顯示,5項(xiàng)研究的分布不完全對(duì)稱,不排除存在發(fā)表偏倚的可能。結(jié)論:現(xiàn)有的證據(jù)表明,六味地黃丸治療PMOP的療效和安全性均優(yōu)于西藥治療。
Abstract:
Objective:To systematically review the clinical outcomes and safety of oral application of Liuwei Dihuang Wan(六味地黃丸,LWDHW)for treatment of postmenopausal osteoporosis(PMOP).Methods:All the randomized controlled trial(RCT)articles about oral application of LWDHW for treatment of PMOP included from May 31,2012 to February 31,2022 were retrieved from the China National Knowledge Internet,Wanfang Database,Vip Database,Cochrane Library and PubMed through computer.The patients in treatment group were treated with oral application of LWDHW or modified LWDHW,while the ones in control group with oral application of Western medicines.Other same therapies could be used in patients of the 2 groups.The articles were retrieved and screened and the information was extracted independently by two researchers according to the inclusion and exclusion criteria,and if any disagreement was found between them,discussion was conducted with another researcher for making a final decision.The bias risk of research in the articles was evaluated by using Cochrane bias risk assessment tools,and then a Meta-analysis on posttreatment pain visual analogue scale(VAS)score,posttreatment bone mineral density(BMD)of lumbar vertebrae from L2 to L4,posttreatment serum level of alkaline phosphatase(ALP)and complication incidence was conducted by using RevMan5.3 software,furthermore,the publication bias was analyzed by using funnel plot.Results:Ten articles(1102 patients)were included in the final analysis,551 patients in each group.The results of Meta-analysis revealed that the posttreatment pain VAS score,posttreatment serum level of ALP and complication incidence were lower,while the posttreatment BMD of lumbar vertebrae from L2 to L4 was higher in treatment group compared to control group(MD=-1.03,95%CI(-1.29,-0.77),P=0.000; MD=-18.02,95%CI(-32.61,-3.43),P=0.020; OR=0.45,95%CI(0.23,0.90),P=0.020; MD=0.06,95%CI(0.02,0.09),P=0.003).Publication bias was analyzed according to funnel plot drawned based on posttreatment BMD of lumbar vertebrae from L2 to L4,and the asymmetrical funnel plot demonstrated that there might be publication bias.Conclusion:Available evidences suggest that the clinical curative effects and safety of LWDHW are better than that of Western medicines in treatment of PMOP.

參考文獻(xiàn)/References:

[1] 王奔,林乾,韓棟,等.絕經(jīng)后女性骨質(zhì)疏松危險(xiǎn)因素分析[J].中國慢性病預(yù)防與控制,2021,29(7):510-513.
[2] 梁文娜,李西海,李燦東.絕經(jīng)后骨質(zhì)疏松的核心病機(jī)——骨痿[J].中國老年學(xué)雜志,2015,35(18):5333-5335.
[3] 盧嚴(yán)方,林貫川,劉倩倩,等.六味地黃丸對(duì)絕經(jīng)期腎陰虛骨質(zhì)疏松癥的基因表達(dá)調(diào)控?cái)?shù)據(jù)分析[J].中國骨質(zhì)疏松雜志,2017,23(3):350-356.
[4] 房謀昊,周航,陳天鵬,等.從“治痿獨(dú)取陽明”論治絕經(jīng)后骨質(zhì)疏松癥[J].中醫(yī)正骨,2021,33(8):49-50.
[5] 王鵬,翁鳳泉,陳述祥.翁鳳泉教授治療絕經(jīng)后骨質(zhì)疏松癥臨證經(jīng)驗(yàn)[J].中國民族民間醫(yī)藥,2021,30(24):84-86.
[6] 郝霞,黃競(jìng)威,吳沛冉,等.淺析周蜻從陰論治絕經(jīng)后骨質(zhì)疏松癥的臨床經(jīng)驗(yàn)[J].遼寧中醫(yī)雜志,2020,47(5):62-64.
[7] 王嘉俊,劉浩,張彥卿.劉浩從肝、脾、腎論治絕經(jīng)后骨質(zhì)疏松經(jīng)驗(yàn)[J].湖南中醫(yī)雜志,2021,37(1):34-35.
[8] LIMOPASMANEE W,CHANSAKAOW S,ROJANASTHIEN N,et al.Effects of the Chinese herbal formulation(Liu Wei Di Huang Wan)on the pharmacokinetics of isoflavones in postmenopausal women[J/OL].Biomed Res Int,2015[2022-03-10].https://pubmed.ncbi.nlm.nih.gov/26146635.
[9] 蘭挨元,王中元,劉彥平.六味地黃丸改善絕經(jīng)后骨質(zhì)疏松癥的臨床觀察[J].中國民間療法,2021,29(21):56-58.
[10] 王文君.六味地黃丸治療絕經(jīng)后骨質(zhì)疏松癥的研究進(jìn)展[J].內(nèi)蒙古中醫(yī)藥,2021,40(12):146-147.
[11] CUMPSTON M,LI T,PAGE M J,et al.Updated guidance for trusted systematic reviews:a new edition of the cochrane handbook for systematic reviews of interventions[J].Cochrane Database Syst Rev,2019,10:142.
[12] 方虹,魯林,陳煒.經(jīng)皮雌二醇聯(lián)合六味地黃丸治療絕經(jīng)期婦女骨質(zhì)疏松癥臨床研究[J].湖北中醫(yī)藥大學(xué)學(xué)報(bào),2019,21(5):28-31.
[13] 李濤.六味地黃丸加味治療肝腎陰虛證絕經(jīng)后骨質(zhì)疏松癥臨床研究[J].醫(yī)藥論壇雜志,2014,35(8):160-162.
[14] 王璽,羅志秀.六味地黃丸聯(lián)合鮭魚降鈣素對(duì)改善絕經(jīng)后骨質(zhì)疏松性疼痛癥狀的臨床研究[J].中國骨質(zhì)疏松雜志,2018,24(11):1485-1488.
[15] 宋博.阿侖膦酸鈉聯(lián)合六味地黃丸口服治療女性絕經(jīng)后骨質(zhì)疏松癥的臨床研究[J].北方藥學(xué),2019,16(2):125-126.
[16] 王久清,張顯,郭慶功,等.阿侖膦酸鈉片聯(lián)合六味地黃丸治療女性絕經(jīng)后骨質(zhì)疏松癥40例臨床觀察[J].中國民族民間醫(yī)藥,2018,27(20):74-76.
[17] 蘭洪文,李紅英.六味地黃丸聯(lián)合鈣爾奇D治療絕經(jīng)后骨質(zhì)疏松的療效分析[J].中外女性健康研究,2016(7):84-85.
[18] 衛(wèi)麗娟.六味地黃丸聯(lián)合鈣爾奇D治療絕經(jīng)后骨質(zhì)疏松癥對(duì)照觀察[J].實(shí)用中醫(yī)內(nèi)科雜志,2012,26(9):54-55.
[19] 李冠儀.六味地黃丸聯(lián)合葡萄糖酸鈣治療原發(fā)性骨質(zhì)疏松癥的臨床研究[D].廣州:廣州中醫(yī)藥大學(xué),2012.
[20] 陳思圓,馮柏淋,郭偉雄,等.六味地黃丸聯(lián)合唑來膦酸治療婦女絕經(jīng)后骨質(zhì)疏松的臨床研究[J]. 現(xiàn)代藥物與臨床,2018,33(5):1140-1144.
[21] 郭小雙,鄭劍南,曹俊青,等.六味地黃丸配合阿侖膦酸鈉治療肝腎陰虛型絕經(jīng)后骨質(zhì)疏松癥的臨床研究[J].湖北中醫(yī)藥大學(xué)學(xué)報(bào),2018,20(2):82-84.
[22] 王雷,李盛華.六味地黃丸治療絕經(jīng)后骨質(zhì)疏松癥作用機(jī)制[J].中國骨質(zhì)疏松雜志,2021,27(7):1042-1049.
[23] 易生輝,招文華,任輝,等.中西醫(yī)治療絕經(jīng)后骨質(zhì)疏松癥的研究進(jìn)展[J].中國實(shí)驗(yàn)方劑學(xué)雜志,2022,28(5):274-282.
[24] 溫明韜,梁學(xué)振,李嘉程,等.基于網(wǎng)絡(luò)藥理學(xué)與分子對(duì)接技術(shù)探討六味地黃丸抗骨質(zhì)疏松癥的機(jī)制研究[J].中國骨質(zhì)疏松雜志,2021,27(8):1129-1134.
(收稿日期:2022-03-16 本文編輯:李曉樂)

相似文獻(xiàn)/References:

[1]李林軍.應(yīng)用膨脹式椎弓根螺釘內(nèi)固定治療合并骨質(zhì)疏松的 胸腰椎退行性疾病[J].中醫(yī)正骨,2015,27(08):49.
[2]李學(xué)朋,朱立國.骨疏康膠囊對(duì)去卵巢大鼠骨小梁的影響[J].中醫(yī)正骨,2015,27(12):12.
　LI Xuepeng,ZHU Liguo.Effect of Gushukang Jiaonang(骨疏康膠囊)on bone trabecula in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(08):12.
[3]陳冠軍,陳揚(yáng),莊汝杰.可灌注骨水泥椎弓根螺釘系統(tǒng) 在老年腰椎疾患手術(shù)中的應(yīng)用[J].中醫(yī)正骨,2015,27(02):40.
[4]王丹輝,賁越,韓梅.林蛙油治療絕經(jīng)后骨質(zhì)疏松癥的臨床研究[J].中醫(yī)正骨,2014,26(01):27.
　Wang Danhui*,Ben Yue,Han Mei..Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(08):27.
[5]黃建華,黃建武,李慧輝,等.加味左歸丸對(duì)絕經(jīng)后骨質(zhì)疏松癥肝腎不足證 患者骨密度的影響[J].中醫(yī)正骨,2013,25(11):19.
　Huang Jianhua*,Huang Jianwu,Li Huihui,et al.Effect of JIAWEI ZUOGUI pill on bone mineral density in postmenopausal osteoporosis patients with deficiency of liver and kidney[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(08):19.
[6]項(xiàng)旻,楊虹,林愛菊,等.絕經(jīng)后2型糖尿病患者骨質(zhì)疏松與血微量元素的關(guān)系研究[J].中醫(yī)正骨,2013,25(12):20.
　Xiang Min*,Yang Hong,Lin Aiju,et al.Clinical study on the relationship between osteoporosis and serum trace elements levels in postmenopausal women with type 2 diabetes[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(08):20.
[7]史曉林,李春雯,張志強(qiáng).弱陽離子磁珠分離技術(shù)和基質(zhì)輔助激光解吸電離飛行時(shí)間質(zhì)譜技術(shù)在原發(fā)性Ⅰ型骨質(zhì)疏松癥血清標(biāo)志蛋白篩選中的應(yīng)用[J].中醫(yī)正骨,2014,26(03):5.
　Shi Xiaolin*,Li Chunwen,Zhang Zhiqiang..Application of magnetic beads based weak cation exchange separation technology and matrix-assisted laser desorption-ionization time of flight mass spectrometry technology in screening serum protein markers of primary type-Ⅰ osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(08):5.
[8]李明,徐明雄,馮左基,等.自擬壯骨方治療絕經(jīng)后骨質(zhì)疏松癥的療效及作用機(jī)制研究[J].中醫(yī)正骨,2014,26(09):21.
　Li Ming*,Xu Mingxiong,Feng Zuoji,et al.Study on the curative effect and mechanism of action of self-made ZHUANGGU decoction in treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(08):21.
[9]陳俊杰,李晴晴,夏瑢.脂代謝及血清內(nèi)脂素水平與絕經(jīng)后骨質(zhì)疏松癥的 相關(guān)性研究[J].中醫(yī)正骨,2012,24(04):16.
　CHEN Jun-jie*,LI Qing-qing,XIA Rong.*.Study on the correlations between the levels of lipid metabolism and serum visfatin and postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(08):16.
[10]許超,肖魯偉,吳承亮.絕經(jīng)后女性骨質(zhì)疏松癥辨證分型與抑郁焦慮的關(guān)系研究[J].中醫(yī)正骨,2011,23(12):3.
　XU Chao*,XIAO Lu-wei,WU Cheng-liang.*.Study on the relationship between the syndrome differ classification and the depression and anxiety for the postmenopausal women with osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2011,23(08):3.
[11]韓艷,溫利平,劉娜,等.補(bǔ)腎活血方對(duì)去卵巢大鼠骨代謝及骨密度的影響[J].中醫(yī)正骨,2015,27(12):7.
　HAN Yan,WEN Liping,LIU Na,et al.Effect of Bushen Huoxue Fang(補(bǔ)腎活血方)on bone metabolism and bone mineral density in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(08):7.
[12]歐國峰,劉鑫,董博,等.絕經(jīng)后骨質(zhì)疏松癥的免疫學(xué)研究進(jìn)展[J].中醫(yī)正骨,2016,28(08):70.
[13]施振宇,劉鐘,陳文亮,等.中醫(yī)綜合療法防治絕經(jīng)后骨量減少的多中心臨床研究[J].中醫(yī)正骨,2017,29(04):1.
　SHI Zhenyu,LIU Zhong,CHEN Wenliang,et al.A multicenter clinical study of complex therapy of traditional Chinese medicine for prevention and treatment of postmenopausal osteopenia[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(08):1.
[14]梁文娜,李西海,李燦東.血清microRNA與絕經(jīng)后骨質(zhì)疏松癥腎虛證的關(guān)系[J].中醫(yī)正骨,2017,29(10):53.
[15]梁文娜,李西海,胡柳,等.二至丸抑制絕經(jīng)后骨質(zhì)疏松大鼠骨代謝紊亂的作用機(jī)制研究[J].中醫(yī)正骨,2017,29(11):1.
　LIANG Wenna,LI Xihai,HU Liu,et al.Study on mechanism of action of Erzhi Wan(二至丸)in inhibiting bone metabolism disorder in rats with postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(08):1.
[16]劉晨,李興勇,姚興璋,等.絕經(jīng)后骨質(zhì)疏松癥的流行病學(xué)概況及發(fā)病機(jī)制研究進(jìn)展[J].中醫(yī)正骨,2018,30(03):52.
[17]楊依然,劉鐘,毛一凡,等.酪蛋白激酶-2相互作用蛋白1基于磷脂酰肌醇3-激酶/蛋白激酶B/哺乳動(dòng)物雷帕霉素靶蛋白通路參與絕經(jīng)后骨質(zhì)疏松癥發(fā)生發(fā)展過程中細(xì)胞自噬的機(jī)制[J].中醫(yī)正骨,2018,30(04):59.
[18]曹俊青,鄭劍南,張麟.右歸丸聯(lián)合阿侖膦酸鈉口服治療絕經(jīng)后骨質(zhì)疏松癥腎陽虛證的臨床研究[J].中醫(yī)正骨,2018,30(05):20.
　CAO Junqing,ZHENG Jiannan,ZHANG Lin.A clinical study of oral application of Yougui Wan(右歸丸)and alendronate sodium for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(08):20.
[19]李中萬,徐紹俊,楊廣鋼,等.健腎方聯(lián)合碳酸鈣D3咀嚼片(Ⅱ) 治療絕經(jīng)后骨質(zhì)疏松癥腎陽虛證[J].中醫(yī)正骨,2018,30(08):11.
　LI Zhongwan,XU Shaojun,YANG Guanggang,et al.Oral application of Jianshen Fang(健腎方)and calcium carbonate and Vitamin D3 chewable tablets(Ⅱ)for treatment of postmenopausal osteoporosis with kidney-yang deficiency syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2018,30(08):11.
[20]趙凡,劉全,吳連國.口服強(qiáng)骨飲聯(lián)合碳酸鈣D3片治療絕經(jīng)后骨質(zhì)疏松癥的臨床研究[J].中醫(yī)正骨,2019,31(04):26.
　ZHAO Fan,LIU Quan,WU Lianguo.Oral applications of Qianggu Yin(強(qiáng)骨飲)and calcium carbonate and Vitamin D3 tablets for treatment of postmenopausal osteoporosis:a clinical study[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2019,31(08):26.

備注/Memo

備注/Memo:
基金項(xiàng)目:長沙市科技計(jì)劃項(xiàng)目(kh2201063) 通訊作者:匡建軍 E-mail:[email protected]
更新日期/Last Update: 1900-01-01